| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 48,895 | 49,185 | 15.04. | |
| 48,875 | 49,220 | 15.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 54,30 | 100 | |||
| 53,00 | 60 | |||
| 50,39 | 170 | |||
| 49,375 | 9 | |||
| 49,365 | 9 | |||
| 49,355 | 9 | |||
| 48,970 | 170 | |||
| 48,955 | 160 | |||
| 48,950 | 170 | |||
| 48,930 | 170 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/brm.htm [/URL] | ||||
| 160 | 48,750 | |||
| 170 | 48,740 | |||
| 170 | 48,720 | |||
| 9 | 48,315 | |||
| 9 | 48,305 | |||
| 9 | 48,295 | |||
| 170 | 47,330 | |||
| 170 | 47,320 | |||
| 110 | 36,600 | |||
| 1.093 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.070 | 0,496 | 1.027 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:28:35 | 48,855 | 5 |
| 17:10:51 | 48,720 | 246 |
| 17:10:48 | 48,720 | 50 |
| 17:10:19 | 48,720 | 100 |
| 14:42:41 | 49,185 | 116 |
| 14:42:41 | 49,190 | 124 |
| Tagesumsatz Xetra | -0,755 -1,52 % | 741 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition? | 6 | Zacks | ||
| Mi | Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers | 2 | BioPharma Dive | ||
| Mi | Raymond James reiterates Market Perform on Bristol-Myers stock | 14 | Investing.com | ||
| BRISTOL-MYERS SQUIBB Aktie jetzt für 0€ handeln | |||||
| Mo | Bristol Myers Squibb evolves and expands multiple myeloma programme | 12 | PMLiVE | ||
| Fr | BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock? | 15 | Zacks |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| Mi | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| Mi | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| Mi | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| Mi | Aurora & Co. vor Höllenritt: Tilray schon durch, aber Berichtssaison könnte Cannabis-Aktien beben lassen | wallstreetONLINE | © Foto: adobe.stock.comDie Quartalsberichtssaison läuft an. Noch plätschert sie vergleichsweise gemächlich dahin. Zunächst stehen die US-Banken im Fokus. Doch in wenigen Tagen wird es auch im Cannabis-Sektor... ► Artikel lesen |